Fiji Kava Limited AI Stock Analysis
Want to see AU:CCO full AI Analyst Report?
Fiji Kava Limited (CCO) AI Stock Analysis
Fiji Kava Limited
(ASX:CCO)
The score is primarily constrained by weak financial performance—ongoing losses, significant cash burn, and a weakened capital structure with negative equity and elevated debt. Valuation is also impaired by negative earnings (negative P/E) and no dividend yield data. Technical analysis contributes little due to missing indicators, resulting in a neutral impact rather than a supportive signal.
Fiji Kava Limited (CCO) vs. iShares MSCI Australia ETF (EWA)
Not enough price history over this period.
- Market Cap
- AUD 2.70M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -2.0
- Beta (1Y)
- -0.01
- Revenue Growth
- 1.01%
- EPS Growth
- 18.18%
- Country
- Australia
- Employees
- 2
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Packaged Foods
Fiji Kava Limited Business Overview & Revenue Model
Company Description
The Calmer Co International Limited is a health and wellness enterprise focused on medicinal kava, conducting its operations in Australia, New Zealand, Fiji, and the United States. This company manufactures and distributes noble kava extract products...
How the Company Makes Money
null
Fiji Kava Limited Financial Statement Overview
Summary
Despite strong revenue scaling, fundamentals remain weak: profitability is still deeply negative (2026 net margin ~-47%), gross margin deteriorated sharply in 2026 (~10% vs ~43% in 2025), operating and free cash flow are materially negative (2026 OCF ~-2.9m; FCF ~-3.0m), and the balance sheet is strained with negative equity (~-0.45m) alongside elevated debt (~3.9m).
Income Statement
22NegativeBalance Sheet
28NegativeCash Flow
24Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.12M | 8.12M | 8.03M | 4.26M | 1.78M | 2.05M |
| Gross Profit | 828.54K | 828.54K | 3.48M | 2.05M | -1.40M | 236.14K |
| EBITDA | -3.00M | -3.00M | -3.24M | -3.34M | -4.86M | -5.72M |
| Net Income | -3.81M | -3.81M | -3.99M | -3.73M | -5.24M | -5.92M |
Balance Sheet | ||||||
| Total Assets | 4.91M | 4.91M | 5.68M | 4.33M | 3.24M | 4.79M |
| Cash, Cash Equivalents and Short-Term Investments | 668.73K | 668.73K | 1.46M | 1.10M | 462.15K | 814.06K |
| Total Debt | 3.88M | 3.88M | 2.31M | 2.21M | 2.35M | 1.78M |
| Total Liabilities | 5.36M | 5.36M | 3.78M | 4.80M | 3.32M | 2.51M |
| Stockholders Equity | -451.34K | -451.34K | 1.90M | -466.84K | -87.53K | 2.28M |
Cash Flow | ||||||
| Free Cash Flow | -2.98M | -2.98M | -4.83M | -2.19M | -3.82M | -7.10M |
| Operating Cash Flow | -2.94M | -2.94M | -4.37M | -2.08M | -3.80M | -6.14M |
| Investing Cash Flow | -47.14K | -47.14K | -459.91K | -116.97K | -21.08K | -964.94K |
| Financing Cash Flow | 2.19M | 2.19M | 5.19M | 2.83M | 3.47M | 6.74M |
Fiji Kava Limited Peers Comparison
Overall Rating
AU:NGS46Neutral- AU:CCO44Neutral
AU:EVE40Underperform
AU:HCT39Underperform
AU:HPC37Underperform
AU:NUC37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| AU:NGS | 46Neutral | AUD 20.25M | -0.01 | -130.72% | ― | -33.05% | 94.22% |
| AU:CCO | 44Neutral | AUD 5.34M | -2.00 | 2884.47% | ― | 1.01% | 18.18% |
| AU:EVE | 40Underperform | AUD 4.93M | -2.03 | -49.07% | ― | -33.53% | 42.98% |
| AU:HCT | 39Underperform | AUD 12.14M | -3.79 | 1795.70% | ― | 0.72% | -486.96% |
| AU:HPC | 37Underperform | AUD 1.08M | -0.36 | -239.37% | ― | ― | ― |
| AU:NUC | 37Underperform | AUD 9.57M | -1.28 | -88.51% | ― | 11.96% | -81.99% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:CCO | Fiji Kava Limited | ― | ― | ― | |
| AU:EVE | EVE Health Group Limited | 0.01 | -0.02 | -56.67% | |
| AU:NUC | Nuchev Pty Ltd | 0.06 | -0.10 | -63.03% | |
| AU:HCT | Holista Colltech Limited | 0.03 | -0.06 | -63.33% | |
| AU:NGS | Nutritional Growth Solutions Ltd. | 0.02 | 0.00 | 15.79% | |
| AU:HPC | Hydration Pharmaceuticals Co. Ltd. | ― | ― | ― |
Fiji Kava Limited Corporate Events
The Calmer Co Securities Reinstated to ASX Quotation
The Australian Securities Exchange has announced that the CCOO security class of The Calmer Co International Limited will be reinstated to quotation, following the company’s compliance with ASX Listing Rule 2.5. This reinstatement means that trading...
The Calmer Co Options Register Reveals Highly Concentrated Ownership
The Calmer Co International Limited has disclosed the distribution of holdings for its options expiring on 20 February 2029, priced at $0.002, showing a highly concentrated ownership structure. The report indicates that 176 holders control approximat...
The Calmer Co Reveals Concentrated Ownership in 2029 Options
The Calmer Co International has released a top holders report for its options expiring in February 2029, priced at $0.002, detailing the ownership structure of this security class. The top 20 option holders collectively own about 66.76% of the 945,27...
The Calmer Co raises $1.82m to fund kava growth and Coles rollout
The Calmer Co International Limited has completed its renounceable rights issue, raising $1.82 million before costs and issuing approximately 1.82 billion new shares and 945 million options, with directors and management fully taking up their entitle...
The Calmer Co. Details ASX Governance Compliance in Appendix 4G Filing
The Calmer Co. International Ltd has lodged its Appendix 4G with the ASX for the year ended 30 June 2026, confirming that its corporate governance statement is available on its website and current as of 26 August 2026. The filing outlines compliance...
The Calmer Co. to Brief Investors on FY26 Progress and Strategic Priorities
The Calmer Co. International Limited, a consumer packaged goods company specialising in kava-based and other natural relaxation and sleep-support products, is expanding its footprint in the functional beverage and wellness markets. It distributes pow...
ASX Suspends Specific Calmer Co Security Class Over Listing Rule Compliance
The Australian Securities Exchange has suspended from quotation a specific class of securities in The Calmer Co International Limited, identified by the code CCOO, under Listing Rule 17.3.4. The halt will remain in effect until the company meets the...
The Calmer Co. builds kava supply and global reach on strong FY26 retail growth
The Calmer Co. International reported strong FY26 performance, highlighted by a 24% quarterly surge in retail sales that made retail its largest revenue channel and set momentum for FY27 growth. The company is leveraging rising global demand for kava...
The Calmer Co. Extends Entitlement Offer to Support Growth in Global Wellness Markets
The Calmer Co. International Limited (ASX: CCO) operates in the natural wellness sector, offering products designed to calm nerves, support mind and muscle relaxation and promote sleep. Its portfolio spans drinking powders, teas, shots, concentrates...
The Calmer Co. Secures Long-Term Pacific Kava Supply to Support Growth
The Calmer Co. International Limited has signed a long-term Strategic Supply Agreement with a leading Pacific-based supplier of premium noble kava, securing reserved capacity of 10 tonnes per month from Papua New Guinea and Vanuatu. The deal, with an...
The Calmer Co Launches Renounceable Rights Offer to Raise A$3.5m
The Calmer Co International Limited has launched a pro rata renounceable entitlement offer, allowing eligible shareholders to subscribe for one new share for every existing share at an issue price of A$0.001, aiming to raise up to A$3.5 million befor...
The Calmer Co. Strikes Strategic Manufacturing Partnership to Scale Global Botanical Extracts
The Calmer Co. International has signed a binding strategic partnership heads of agreement with Kaiming Agro Processing’s subsidiary Pacific Culture and Heritage to develop a long-term manufacturing alliance for kava, ginger and turmeric CO₂ extracts...
The Calmer Co. Begins Trading Entitlement Offer Rights on ASX
The Calmer Co. International Limited has begun trading rights for its renounceable entitlement offer on the ASX under code CCOR, following the announcement of the offer and lodgement of the associated prospectus and documentation. The timetable outli...
The Calmer Co Clarifies Terms of Free-Attaching Options in ASX Capital Raise
The Calmer Co International Limited has lodged an updated notice with the ASX regarding a proposed pro rata renounceable issue of securities, clarifying that the associated options are free-attaching and carry no issue price. This clarification refin...
The Calmer Co. Revises Timetable for A$3.5m Entitlement Offer
The Calmer Co. International Limited has updated the indicative timetable for its pro-rata renounceable entitlement offer, which is intended to raise up to A$3.5 million from existing shareholders. The offer schedule now spans late July to late Augus...
The Calmer Co Unveils Major Renounceable Entitlement Offer
The Calmer Co International Limited, listed on the ASX under the code CCO, operates in the consumer health and wellness sector, focusing on products designed to support relaxation and stress relief. The company targets retail and investor markets thr...
The Calmer Co launches $3.5m renounceable rights issue to fund growth and repay notes
The Calmer Co International Ltd has announced a pro rata renounceable entitlement offer to raise up to approximately $3.5 million before costs, through a 1-for-1 rights issue priced at A$0.001 per new share with one free attaching option for every tw...
The Calmer Co Issues New Shares on Option Exercise, Affirms Compliance
The Calmer Co International Limited, an ASX-listed beverage and wellness company, develops and sells kava-based and other natural products that offer alternatives to alcohol and promote relaxation and sleep. Its products, sold under the Fiji Kava, Ta...
The Calmer Co Seeks Quotation for New ASX Shares
The Calmer Co International Limited has applied for quotation of 632,988 new ordinary fully paid shares on the ASX, with an issue date of July 3, 2026. The securities arise from the exercise of options or conversion of other instruments, modestly exp...
The Calmer Co. Wins Coles Listing for New Fiji Kava FZZR as It Targets U.S. Retail Growth
The Calmer Co. has secured Coles ranging for its new Fiji Kava FZZR kava product, an innovative effervescent supplement format that can be dissolved, chewed or taken direct-to-mouth and will be regulated as a complementary medicine under Australia’s...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 06, 2026